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Abstract
In the past decade, a high incidence of somatic mitochondrial DNA (mtDNA) mutations has been observed, mostly based on
a fraction of the molecule, in various cancerous tissues; nevertheless, some of them were queried due to problems in data
quality. Obviously, without a comprehensive understanding of mtDNA mutational profile in the cancerous tissue of a
specific patient, it is unlikely to disclose the genuine relationship between somatic mtDNA mutations and tumorigenesis. To
achieve this objective, the most straightforward way is to directly compare the whole mtDNA genome variation among
three tissues (namely, cancerous tissue, para-cancerous tissue, and distant normal tissue) from the same patient.
Considering the fact that most of the previous studies on the role of mtDNA in colorectal tumor focused merely on the D-
loop or partial segment of the molecule, in the current study we have collected three tissues (cancerous, para-cancerous
and normal tissues) respectively recruited from 20 patients with colorectal tumor and completely sequenced the
mitochondrial genome of each tissue. Our results reveal a relatively lower incidence of somatic mutations in these patients;
intriguingly, all somatic mutations are in heteroplasmic status. Surprisingly, the observed somatic mutations are not
restricted to cancer tissues, for the para-cancer tissues and distant normal tissues also harbor somatic mtDNA mutations
with a lower frequency than cancerous tissues but higher than that observed in the general population. Our results suggest
that somatic mtDNA mutations in cancerous tissues could not be simply explained as a consequence of tumorigenesis;
meanwhile, the somatic mtDNA mutations in normal tissues might reflect an altered physiological environment in cancer
patients.
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Introduction
In the past decade, the role of mitochondrial DNA (mtDNA)
mutation in tumorigenesis has received much attention. A high
incidence of somatic mtDNA mutations, mostly in homoplastic,
has been identified in nearly all types of cancerous tissues [1,2].
Nonetheless, the relationship of somatic mtDNA mutations and
tumorigenesis has been hotly debated. Some studies suggested that
the mtDNA somatic mutations likely result from the elevated
reactive oxygen species (ROS) in tumor cell [3,4,5], because most
of these mutations are T to C and G to A base transitions [1,2],
similar to the mutation pattern of oxidative decay on DNA [6,7].
It was also suggested that some changes in mtDNA could disable
the function of mitochondrial respiratory chain and thus
contribute to tumor procession [8,9,10,11]. For example, a recent
study suggested that mtDNA mutations which produce the
deficiency in respiratory complex I activity could contribute to
tumor progression by enhancing the metastatic potential of tumor
cells [12]. In contrast, some studies suggested that the somatic
mutation in tumor tissue could simply arise by chance in tumor
progenitor cells without any physiological advantage or tumori-
genic requirement [13,14]. Indeed, Vega and colleagues found
that a lot of mtDNA mutations detected in tumor were in fact the
common polymorphisms or mutational hotspots prevailing in
human general populations, leading the authors to propose that
these somatic mutations are more likely to be neutral [15].
Similarly, the functional roles of some of the identified somatic
mtDNA mutations were queried largely due to the problems in
data quality [16,17,18]. Obviously, further evidence is needed to
elucidate the exact role that somatic mtDNA mutations have play
in tumorigenesis.
In the present study, we performed the whole mitochondrial
genome screening for somatic mutation in paired cancerous and
non-cancerous tissues from 20 patients with colorectal cancer. By
using the same quality control measures as adopted in our previous
studies in complete mtDNA sequencing [19,20,21,22], we want to
get a deeper insight into the profile of the mtDNA somatic
mutations in colorectal cancer. The direct comparison of the
entire mtDNA sequences of the primary cancerous, matched para-
cancerous normal and distant normal tissues from the same
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adopted to disclose a detailed profile of mtDNA somatic mutations
in both normal and tumor tissues in the same patient. Our results
revealed that the observed somatic mutations in our samples are
much less frequent than the previous studies. Surprisingly, all the
observed somatic mutations are in heteroplasmic state, an
observation quite different from the previous studies.
Result
A total of 59 complete mitochondrial genome sequences of three
paired tissues from 20 colorectal cancer patients were obtained in
this study, and all the sequences have been deposited into
GenBank (http://www.ncbi.nlm.nih.gov/Genbank/) with acces-
sion numbers GU392048–GU392106. All the mtDNA variable
sites of each tissue have been displayed on a schematic tree
(Figure 1), which could provide a direct comparison of the entire
mtDNA genome variation among three tissues from the same
patient and thus allow pinpointing the somatic mutation(s) in a
patient conveniently. As demonstrated in Figure 1, six of 20
patients carried mtDNA somatic mutations in their cancerous
tissues, occupying a much lesser proportion (6/20; 30%) than
many previous reports. For example, Tan et al. found 27 somatic
mutations in 14/19 (74%) breast patients [23]; Zhu et al. found 45
somatic mutations at 35 nucleotide position in 14/15 (93%) breast
cancer patients [24]; in Polyak et al. (1998), 7/10 (70%) colorectal
tumor cases were demonstrated to carry one to three mutations.
In total, there are 18 somatic mutations were detected in the 59
tissue samples under study (Figure 1 and Table S1), and all the
somatic mutations occur merely on the terminal branches of
phylogenic tree, and no haplotype-shift was observed. With the
exception of the RNA-coding genes (including sRNA and tRNA),
these somatic mutation sites are dispersed across the entire
mtDNA genome, which seems quite different from the mutation
spectrum observed in patients with mitochondrial diseases [25,26].
Specifically, seven mutations locate in the D-loop region, whereas
the remaining 11 locate in protein-coding regions. Among the 11
coding-region somatic mutations, only two (i.e., G4532A and
A9275G) are synonymous transitions which occur on two unstable
sites; whereas the rest nine mutations all are non-synonymous
substitutions that locate at positions 6718, 14288, 15332, 15447,
and 15276, most of which are evolutionarily highly conserved after
compared with the mitochondrial genomes from 13 different
vertebrate species (Table S1). By further evaluating the conserva-
tion of these five mutational sites among a total of published 3,635
complete mitochondrial genome sequences from general human
populations, our results revealed that all of the five sites are highly
conserved among the general human populations as well (Table
S1). Surprisingly, in spite of the high conservation of site 6718,
heteroplasmic variation 6718A/G presents in both the cancer and
the para-cancer normal tissues of Patient 1, raising the possibility
that the para-cancer normal tissue has likely been invaded by
cancer cells. Indeed, a similar pattern is observed in Patient 3, in
which its cancer and para-cancer tissues share the same
heteroplasmic variation 16365C/T. This observation, again,
emphasizes the particular necessity of the inclusion of the distant
normal tissue for analysis.
Intriguingly, as shown in Figure 1, the pinpointed mtDNA
somatic mutations are not restricted merely to tumor tissues, for
we did have observed some somatic mutations in the normal
tissues of Patients 1, 3, 8, 14, and 20. Specifically, transition 14288
seems to be a recurrent mutation site because it appears in three
patients belonging to different haplogroups. This non-synonymous
mutation presents only in normal tissues of the patients. The
14288 site itself is not conserved across different species but seems
to be quite conserved among human populations; whether this
mutation has functional effect is unknown.
In Patient 14, site 16093 in cancerous tissue is homoplastic C,
while in para-cancerous normal and distant normal tissue this site
shifts to be heteroplasmic as C/T. This pattern was confirmed by
DHPLC assay result: in cancerous tissue C14 site 16093 displays a
single peak, whereas in para-cancerous normal and distant normal
tissues it shows double peak (Figure 2). Of note is that site 16093
itself is a hot spot in the general population and mutation on this
site has also been found in normal tissue of cancer patients in other
studies [27]. Similar phenomenon also happened to Patient 20, in
which only distant normal tissue harbored somatic mutation (viz.,
A9275G). These mtDNA somatic mutations might be irrelevant to
tumorigenesis considering their appearance in the normal tissues.
Discussion
Hitherto, most of the previous studies on the role of mtDNA in
colorectal tumor focused merely on the D-loop or partial segment
of the molecule [28,29,30,31], only a few reports have focused on
the mutational profile on its whole genome (Polyak et al. 1998). To
get more insights into the relationship between mtDNA and
colorectal tumor, in the current study we have recruited three
tissues (cancerous, para-cancerous and normal tissues) sampled
from 20 patients with colorectal tumor; by sequencing the entire
mtDNA genome from each tissue and comparing the mutational
difference among three tissues from the same patient, our study
revealed a relatively low mutational frequency and the hetero-
plasmic status of all the observed somatic mutations. These
observations are quite different from the previous studies,
emphasizing the complexity in the etiology of colorectal tumor.
Since most of the patients (12/20) under study do not harbor
any mtDNA somatic mutation in their cancerous tissues, one
explanation could be that it is the modification in nuclear genome
which has contributed to the tumorigenesis in the samples without
involving any mtDNA changes. The frequency of mtDNA somatic
mutations (6/20; 30%) observed in our current study, which is
comparable to our previous results on breast cancer (2/10; 20%
[22]), but is significantly lower (p,0.05) than the previous
observations, especially those on colorectal tumor. For example,
Polyak et al. found that 7/10 (70%) colorectal tumor patients
carried one to three mutations [32]. It is possible that the somatic
mutation frequency may vary among different ethnic populations
or correlate with the cancer stages; testing this possibility would
require a systematic design of the study in near future.
Alternatively, the much lower incidence of somatic mutations
observed in our study is most plausibly attributed to the stringent
quality control that was adopted during the data generation and
analysis. Indeed, when the potential problems pinpointed in the
earlier studies by using a phylogenetic approach [18] were
excluded, the frequency of somatic mutations would then decrease
considerably.
Intriguingly, all the somatic mutations identified here are in
heteroplasmic, which is quite different from the previous
observations. Especially, some of the somatic heteroplasmic
mutation also present in the normal tissues of the cancer patients.
Similarly, Taylor and colleagues also found mtDNA somatic
mutations in the normal tissue in colorectal tumor patients, and
most of these mutations were heteroplasmic [33]. To evaluate
whether the heteroplasmic mtDNA somatic mutations detected in
the normal tissues of cancer patients is a normal phenomenon, we
investigated the frequency of heteroplasmic mtDNA somatic
mutations in the general human populations (embracing a total of
Colorectal Cancer and mtDNA Mutations
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Our result revealed that the frequency of individuals harboring
heteroplasmic somatic mtDNA mutation(s) is less than 4%,
suggesting that heteroplasmy in mtDNA from the general
population is a rare phenomenon, at least when detected by
direct DNA sequencing method [34,35,36]. Then we thoroughly
reviewed the previous studies on mtDNA mutation in different
tumor types and found that heteroplasmic somatic mtDNA
mutations were also observed in the normal tissues of cancer
patients [9,22,27,33,37], with a significant higher frequency
(38.6%) than in the general population (3.2%; p,0.001) but still
lower than that in the cancerous tissue (52.9%; p,0.05) (Table
S2). Since each individual is characterized by a mixture of related
mitochondrial haplotypes, and widespread heteroplasmy in the
mtDNAs of various normal human tissues does have been
observed [27,38,39,40]. It is likely that the observed difference
in the frequencies of the heteroplasmic mutations between the
normal tissue of tumor patients and the general population
(commonly adopting their peripheral blood) is attributed to the
heteroplasmy between different tissues. Alternatively, the increased
heteroplasmic mutation frequency, in both cancerous and
matched normal tissues in tumor patients relative to the general
population (Table S2), might result from an altered physiological
environment (maybe the elevated level of ROS, or some other
Figure 1. Phylogenetic tree of 59 complete mtDNA sequences from colorectal normal and malignant tissues. Haplogroup names are
inserted along the branches determining the locations of the corresponding ancestral haplotypes. Variants (reconstructed most parsimoniously) on
uninterrupted branches are listed arbitrarily in ascending order. Suffixes ‘‘A, C and T’’ indicate transversions, ‘‘ins’’ indicates a nucleotide insertion; ‘‘C/
T, A/C, and A/G’’ suggest heteroplasmic mutations, ‘‘d’’ indicates a deletion. Recurrent variants are underlined. Length variation of C-tract around
positions 310 and 16189 is not indicated in the figure. Suffixes ‘‘C, CP, and CN’’ in the sample names indicate ‘‘cancerous tissue, para-cancerous tissue
and normal tissue’’ respectively.
doi:10.1371/journal.pone.0021613.g001
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that both tumor and matched normal tissues from prostate cancer
patients exhibit significantly higher expression of spermine oxidase
[41], which has been linked to increased ROS and DNA damage
[42,43], versus tissues from prostate disease-free patients.
In retrospect, previous studies have demonstrated that
mtDNA mutation with potential functional effect could
contribute to tumor procession [8,12]. In the present study,
the identified somatic mtDNA mutations in coding region all
located in evolutionarily highly conserved sites. Therefore, it
seems possible that these somatic mutations, albeit all in
heteroplasmic, might have played some roles in affecting the
function of respiratory chain and thus have some biochemical
functional effect to its host cell. However, considering that most
of the patients do not harbor somatic mutations in the cancerous
tissues, whether the functional effect of these somatic mutations
are necessary for the host cell remains unknown. As to the
somatic mtDNA mutations present in normal tissues, they
should reflect an altered microenvironment for the mtDNA.
Whether these mutations, plus the interaction with the altered
microenvironment, could increase the susceptibility for a cell to
tumorigenesis is unknown.
In total, understanding the relationship between mtDNA
somatic mutations and tumorigenesis is a challenging task, because
strategies that directly estimating cell fates or tracing the detailed
process of both events are still impractical in vivo. By direct
comparing mtDNA genome variation in three paired tissues from
the same patient, our study could provide an extensive profile of
the somatic mtDNA mutation in tumor patient. A low frequency
somatic mtDNA mutation was identified in the colorectal patients
and all the mutations were heteroplasmic. Meanwhile, some
somatic mutations could be present in the normal tissue which
indicates that these somatic mutations are not the consequence of
tumorigenesis, and it might reflect a changed physiological
environment for the mtDNA in tumor patient.
Materials and Methods
Clinical samples
A total of 59 tissue samples were collected in this study, including
the primary colorectal cancerous tissues (C1–C10), corresponding
para-cancerous normal tissues (CP1–CP10) and distant normal
tissues (CN1–CN10), which were taken from 20 Chinese patients
with colorectal cancer during surgery with informed consent. The
cancerous tissue was confirmed by HE-stained slides of the frozen
section after surgery, whereas the para-cancerous normal tissue was
obtained from the normal tissue surrounding the cancer, and the
distant normal tissue is at least 5 cm away from the edge of the
cancer tissue. All the patients were clinically diagnosed with stage I
(T1–T2, N0, M0) colorectal cancer according to the clinical
standard for the category of the cancer [44]. Since the major
objective of our study is to pinpoint the subtle difference between
cancer and the matched normal tissues from the viewpoint of
mitochondrial genome, only the colorectal normal tissues (including
the para-cancerous and distant normal tissues) from the same
patient were therefore taken into consideration. The para-
cancerous normal tissue was not available for Patient 19. The study
was performed according to the Declaration of Helsinki.
DNA amplification and sequencing
Total genomic DNA was respectively extracted from the para-
cancerous tissue, primary cancerous tissue and distant normal tissue
by using the standard phenol/chloroform method. The entire
mtDNA genomes were amplified and sequenced as fully described
in our previous studies [19,20,21,22]. Sequencing data were edited
and aligned by use of the DNASTAR software (DNAStar Inc.,
Madison, Wisc.), and mutations were scored relative to the revised
Cambridge reference sequence (rCRS) [45]. The phylogenetic status
of each mtDNA was determined according to the reconstructed East
Asian mtDNA phylogeny [20,46], and their relationships were
illustrated by way of a schematic phylogenetic tree (Figure 1).
Figure 2. DHPLC assay of the heteroplasmic somatic mutations. Direct sequencing demonstrate that nucleotide site 16093 displays a
homoplastic C in cancerous tissue, while in para-cancer normal and distant normal tissue this site is in heteroplasmic status of T/C. DHPLC assay
confirmed the sequencing result: in tissue C14 it displays a single peak, whereas in CP14 and CN14 it shows double peak.
doi:10.1371/journal.pone.0021613.g002
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To avoid potential problems and errors observed in the
published mtDNA disease studies [18,47,48,49], a stringent
quality-control procedure [19,20,21] was utilized in the course
of sample handling and data generation. In addition, to fully avoid
artificial recombination triggered by sample mix-up or contami-
nation [18,50], each tissue sample was amplified and sequenced
individually as we have done before [22].
Determination of heteroplasmy by DHPLC
For the observed heteroplasmic mutation during the direct
DNA sequencing, we further confirmed it by denaturing high-
performance liquid chromatography (DHPLC) (Figure 2).
Supporting Information
Table S1 Somatic mtDNA mutations identified in 20 colorectal
patients
(DOC)
Table S2 Comparison of the frequency of individuals harboring
heteroplasmic mtDNA mutations in normal population and in
cancer patients.
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